Teriparatide acetate (CAS 52232-67-4) is a high-purity, pharmaceutical-grade Bone Anabolic Agent produced via advanced recombinant DNA technology, fully complying with USP and EP quality standards. As a synthetic fragment of human parathyroid hormone (PTH), its molecular structure is engineered to activate PTH receptors in osteoblasts, stimulating bone formation, enhancing bone mineral density, and improving bone microarchitecture. Produced with strict control over protein purity (≥99%) and biological activity, each batch undergoes rigorous osteogenic function validation, making it a reliable raw material for osteoporosis drug formulation.
This potent recombinant peptide stands out for its unique bone-building mechanism—unlike traditional anti-osteoporosis drugs that merely inhibit bone resorption, it actively promotes new bone growth to reverse bone loss. It effectively reduces fracture risk in postmenopausal women and men with osteoporosis, with a well-documented safety profile for long-term administration. Its stable structure supports formulation into injectable solutions, enabling convenient subcutaneous dosing that fits seamlessly into patients’ daily routines.
Teriparatide acetate (CAS 52232-67-4) caters to professional users: pharmaceutical manufacturers developing bone health medications, orthopedic clinics, and research institutions studying bone metabolism. Its clinically proven efficacy, pharmaceutical-grade purity, and targeted bone-anabolic action make it a top choice for buyers prioritizing reliability and therapeutic innovation. Whether for large-scale commercial production or preclinical research, this Bone Anabolic Agent meets the stringent demands of the global orthopedic pharmaceutical sector.
